No connection

Search Results

KYNB vs TELA

KYNB
Kyntra Bio, Inc.
BEARISH
Price
$7.17
Market Cap
$29.0M
Sector
Healthcare
AI Confidence
95%
TELA
TELA Bio, Inc.
BEARISH
Price
$0.63
Market Cap
$28.2M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
KYNB
--
TELA
--
Forward P/E
KYNB
-0.7
TELA
-1.12
P/B Ratio
KYNB
-0.97
TELA
4.44
P/S Ratio
KYNB
4.51
TELA
0.35
EV/EBITDA
KYNB
0.13
TELA
-1.07

Profitability

Gross Margin
KYNB
-273.8%
TELA
68.17%
Operating Margin
KYNB
-1058.65%
TELA
-31.86%
Profit Margin
KYNB
2848.63%
TELA
-48.37%
ROE
KYNB
--
TELA
-223.35%
ROA
KYNB
-16.96%
TELA
-25.12%

Growth

Revenue Growth
KYNB
-59.3%
TELA
18.2%
Earnings Growth
KYNB
--
TELA
--

Financial Health

Debt/Equity
KYNB
4.37
TELA
9.13
Current Ratio
KYNB
3.39
TELA
4.21
Quick Ratio
KYNB
3.19
TELA
3.4

Dividends

Dividend Yield
KYNB
--
TELA
--
Payout Ratio
KYNB
0.0%
TELA
0.0%

AI Verdict

KYNB BEARISH

KYNB exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio (-0.97), indicating that liabilities exceed assets. While the company maintains a healthy current ratio (3.39), the underlying fundamentals are deteriorating with a YoY revenue decline of 59.30% and a catastrophic 5-year price depreciation of 98.6%. The reported profit margin is a mathematical anomaly likely driven by a one-time non-operating gain, as the operating margin remains deeply negative at -1058.65%. Despite a lone analyst's aggressive price target of $43.00, the deterministic data suggests a high risk of insolvency or further dilution.

Strengths
Strong short-term liquidity (Current Ratio 3.39)
Quick ratio (3.19) suggests sufficient liquid assets for immediate obligations
Recent 1-year price performance is slightly positive (+10.3%)
Risks
Negative equity (Price/Book -0.97) indicating technical insolvency
Severe revenue contraction (-59.30% YoY)
Extremely poor financial health (Piotroski F-Score 1/9)
TELA BEARISH

TELA exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a catastrophic ROE of -223.35%. While the company maintains a strong gross margin (68.17%) and modest revenue growth (18.2%), these are completely offset by extreme leverage (Debt/Equity of 9.13) and a consistent 25-quarter history of negative earnings. The stock's 5-year price collapse of 95.4% reflects a fundamental loss of investor confidence that is not countered by any meaningful insider buying or operational profitability.

Strengths
Strong Gross Margin of 68.17% indicating product value
Positive YoY Revenue Growth of 18.20%
High Current Ratio (4.21) providing short-term liquidity
Risks
Extreme financial leverage with a Debt/Equity ratio of 9.13
Severe lack of profitability with an ROE of -223.35%
Critical financial health as indicated by a Piotroski F-Score of 1/9

Compare Another Pair

KYNB vs TELA: Head-to-Head Comparison

This page compares Kyntra Bio, Inc. (KYNB) and TELA Bio, Inc. (TELA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile